Evidence map›Paper›PMID 36113898›Full record

ArticleBMJ open quality2022

Increasing statin prescription rates to prevent cardiovascular disease among high-risk populations: a quality improvement intervention centred on a novel interactive tool.

Sana Rashid, Giselle Alexandra Suero-Abreu, Maciej Tysarowski, Hyo-Bin Um, Kajol Shah, Yawen Zhang, Analise Douglas, Daniel Matassa

Abstract read
In one paragraph

Article in BMJ open quality, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sana RashidDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA rashidsana50@gmail.com.ORCID 0000-0003-3740-9857
Giselle Alexandra Suero-AbreuDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Maciej TysarowskiDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Hyo-Bin UmDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Kajol ShahDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Yawen ZhangDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Analise DouglasDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Daniel MatassaDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statins are indicated for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Our previous study of 1042 consecutive patient encounters at our large urban academic institution found that one in five patients were not prescribed an appropriate statin therapy. Only one-third of patients had follow-up cholesterol levels ordered to monitor treatment efficacy. In order to improve adherence to cholesterol guidelines at our institution, a quality improvement project was undertaken. We implemented interventions over a 4-month period to improve statin prescription rates: (a) development of an online interactive tool, (b) physician education on updated cholesterol guidelines and utilisation of the tool, (c) display of guideline summary in the workspace and (d) a documentation reminder in the electronic health record. We randomly selected encounter dates, from which 622 consecutive patient encounters were analysed. The primary outcome measures were prescription rates of statins, documentation of a 10-year ASCVD risk score and follow-up cholesterol levels ordered to monitor treatment efficacy. Out of the 622 patient encounters, 232 met statin indication. In this post-intervention group, statin prescription rates improved when compared with the pre-intervention group (90.5% vs 82.3%, p=0.006). Among patients who met statin indication solely via a 10-year ASCVD risk score ≥7.5%, there was an increase in documentation of the calculated 10-year ASCVD risk score (72.3% vs 57.8%; p=0.039) and in statin prescription rate (90.8% vs 67.6%; p<0.001). In addition, there was an increase in follow-up cholesterol levels ordered in all patients included in our study who met statin indication (64.1% vs 33.3%; p<0.001). Our quality improvement project showed higher rates of statin prescription, 10-year ASCVD risk score documentation and treatment monitoring after multiple interventions, centred on an easily accessible online interactive tool.

Indexed as

AtherosclerosisCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterolHumansPrescriptionsQuality ImprovementRetrospective StudiesCholesterolHydroxymethylglutaryl-CoA Reductase Inhibitorshealthcare quality improvementprimary carequality improvement methodologiesremindersstaff development

Identifiers

PMID36113898
PMCPMC9486342

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.